Methodology: each issue's direction is a live signal — long/short opens or holds a position, neutral means flat, and every direction change opens, flips, or closes it. Returns are direction-aware (a short gains when the price falls) and compound across positions from first observation to the latest issue. "Price move" is the stock's own raw change, shown separately. Neither represents actual portfolio performance.
Brief History (20 issues)
Down 1.25%, back-testing the SMA20/50 shelf at 228–231 as the Walgreens distribution overhang lingers. Displaced volumes could still land in Cardinal's lap and 20 analysts see 18% upside—holding above 231, stop on a close below 228.
Dragged down 2.54% by Cencora's Walgreens headline, yet the displaced distribution volume could well land in Cardinal's lap; RSI 53 holds above all three moving averages after a +25.6% three-month run and 20 analysts see 15.7% upside — sympathy damage, not thesis damage, staying long
Up 1.30% against the tape with RSI at a healthy 62.1 above every average; with 19 analysts leaving only 7.2% of upside, this is drug distribution's steadiness rather than its torque — position maintained.
Up 0.33% with RSI at 58.8, above every moving average and 3.1% from its high; the defensive profile of pharma distribution has allocation value ahead of CPI — position maintained.
Down 0.53% with RSI healthy at 58.0 and price 3.5% below its high; defensive pharma-distribution cash flow retains allocation value as cut expectations warm. Maintaining the long.
Down 0.66% with RSI healthy at 59.8 and price just 2.9% below the $244.87 high; defensive pharma-distribution cash flow cushioned a turbulent day. Maintaining the long.
A defensive drug-distribution name grinding higher, ~7% consensus upside — hold. Steady cash flow but limited upside.
Down 0.87% with RSI firm-neutral at 56.5 and price 4.0% off its high, on stable pharma-distribution cash flow. Maintaining the long.
RSI at 59.5 and only 3.1% below the $243.21 high, as defensive pharma-distribution cash flow keeps attracting rotation flows; maintaining the long.
Up 1.38%, with healthcare distribution benefiting from the sector rotation (XLV +2.36%). 21 analysts target $255.60 for 9.9% upside amid bullish moving-average alignment — continue holding
Position: +2.5% in the drug-distribution cash machine, 7% off the high, hold
Steady drug-distribution cash flows 6.6% off the high with 21 analysts at +12% — hold
Flat-ish, -0.09% at $228.5. TD Cowen lifts to $275, BofA to $260, full-year EPS guide already raised. Coiling into the 8/11 print — stay long.
Up 1.7% to $228.72 as drug distribution joins the old-economy healthcare counterattack; holding
Down 2.3% to $224.94 in the healthcare giveback (Elevance shrapnel) — structure intact above the 50-day; holding
Down 0.9% to $233.66 — normal noise near the highs; the drug-distribution slow bull holds
Up 0.9%, back at 52-week highs; the drug-distribution slow bull is open for business as usual — holding
Down 1.4%, a second breather at the highs; giving back after a 15% month doesn't bend the trend — the 20-day ($231) is the line
Down 1.1% — the first breather after 52-week highs; up 17% on the month, any dip is generosity, holding
+0.9% to fresh 52-week highs, +18% month; drug distribution with defense and momentum